Evidence map›Paper›PMID 33168307›Full record

ArticleGynecologic oncology2021

Manipulating the Wnt/β-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy.

J A Wall, S Meza-Perez, C B Scalise, A Katre, A I Londoño, W J Turbitt, T Randall, L A Norian, R C Arend

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gynecologic oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
5.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 50 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. The role of Evi/Wntless in exporting Wnt proteins.Development (Cambridge, England) · 2023
    Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Metabolic Alterations and WNT Signaling Impact Immune Response in HGSOC.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

J A WallDepartment of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
S Meza-PerezDivision of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
C B ScaliseDepartment of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
A KatreDepartment of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
A I LondoñoDepartment of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
W J TurbittDepartment of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
T RandallDivision of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
L A NorianDepartment of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL 35294, USA; O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
R C ArendDepartment of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, AL 35294, USA. Electronic address: rarend@uabmc.edu.
University of Alabama at Birmingham · US

Funding

UAB Cancer Prevention and Control Training Program (T32)T32CA047888 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Ritu Aneja, Ellen Mary Lavoie Smith · 2018 to 2026
$3.2M
Research Training Program in Basic and Translational OncologyT32CA183926 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BHATIA, RAVI · 2014 to 2018
$1.0M
NCI NIH HHS T32 CA047888NCI NIH HHS T32 CA183926
6 · The paper itself

Abstract

objectiveImmune checkpoint blockade (ICB) therapy shows limited efficacy in ovarian cancers due to the "cold" immune phenotype surrounding these tumors. Previous studies have shown that in ovarian cancer Wnt/β-catenin pathway activation contributes to this immune phenotype. Here, we evaluated the anti-tumor and immune-enhancing properties of the Wnt inhibitor, CGX-1321, used alone or in combination with either DKN-01 or anti-PD-1 therapy, in pre-clinical ovarian cancer models.

methodsThe parental ID8 murine ovarian cancer model harboring a knock-out of p53 (ID8p53

resultsCGX-1321 significantly reduced tumor burden and constrained tumor progression in the ID8p53

conclusionsCGX-1321 significantly reduced tumor burden and enhanced CD8+ T cell levels in ovarian cancer, nevertheless the addition of DKN-01 or anti-PD-1 therapies did not enhance these effects of CGX-1321. Further investigation is needed to determine if CGX-1321 + DKN-01 combination treatment sensitizes pre-clinical ovarian cancer to ICB therapy.

Indexed as

AcyltransferasesAnimalsAntineoplastic Combined Chemotherapy Protocolsbeta CateninCD8-Positive T-LymphocytesCell Line, TumorDrug SynergismEnzyme InhibitorsFemaleImmune Checkpoint InhibitorsIntercellular Signaling Peptides and ProteinsLymphocytes, Tumor-InfiltratingMembrane ProteinsMiceMice, Inbred C57BLMice, KnockoutAcyltransferasesbeta CateninCTNNB1 protein, mouseDkk1 protein, mouseEnzyme InhibitorsImmune Checkpoint InhibitorsIntercellular Signaling Peptides and ProteinsMembrane ProteinsPorcn protein, mouseWnt ProteinsImmune checkpoint blockade (ICB) therapyOvarian cancerTumor microenvironment (TME)Wnt/β-catenin signaling

Identifiers

PMID33168307
PMCPMC9107782
OpenAlexW3095555125

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.